Join Craig E. Herrman, MD, Director of JWM Neurology Research, as he presents a brief talk on the basics of Multiple Sclerosis. This is geared toward patients and families.
Neurologist Matthew G. Gentry, MD, has joined JWM Neurology. Dr. Gentry received his Medical Degree in 2011 at Indiana University School of Medicine in Indianapolis. He completed his Neurology Residency in 2015, also at IU School of Medicine, where he was Chief Resident. Dr. Gentry recently completed his Fellowship in Clinical Neurophysiology with an emphasis in EEG and Epilepsy at IU School of Medicine. He sees patients with all neurologic conditions and has special interests in the areas of Epilepsy, EEG, neuromuscular conditions and EMG.
JWM Neurologist, Dr. David Glander, was recently featured on the Dick Wolfsie Show on WISH TV 8. Watch the 4 video interview demonstrations of exciting TeleStroke technology that is being utilized.
The physicians at JWM Neurology welcome neurologist, Kevin J. Puzio, MD. Dr. Puzio sees adult patients in our Indianapolis offices with all types of neurologic disorders.
Central Indiana Neurology (CIN) located in Anderson, Indiana has joined JWM Neurology.
Our collaborative partnership together will enable us to combine and serve a larger geographic area in Central Indiana as well as continue to better serve our patients and referring physicians. Between JWM and CIN, we now have eleven locations including offices in: Indianapolis, Carmel, Mooresville, Franklin, Kokomo, Anderson and Elwood.
JWM welcomes Central Indiana Neurology physicians, Larry Blankenship, MD, Charles Howe, MD, Christopher Rocco, MD, Caroline Stevens, DO and their staff.
Northwest Radiology and JWM Neurology, both located in Indianapolis, are partnering together to offer the first and only FDA-approved
diagnostic PET-CT (Positive Emission Tomography-Computed Tomography) tracer for imaging beta-amyloid neuritic plaques in the living
brain. For the first time in clinical practice, physicians are now able to utilize PET-CT scanning to see evidence of amyloid plaques
(deposits in the gray matter associated with brain degeneration) when evaluating patients for Alzheimer’s disease and other causes
of cognitive decline. Currently, only a neuropathological exam (performed during an autopsy) can definitively diagnose Alzheimer’s